Trials / Recruiting
RecruitingNCT05768464
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
A Prospective, Multicenter, Single-arm Clinical Study of the Efficacy and Safety of Toripalimab in Combination With Axitinib for Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with high-risk recurrence factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | 240mg intravenously every 3 weeks |
| DRUG | Axitinib | 5mg orraly twice daily |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
- First posted
- 2023-03-14
- Last updated
- 2023-03-14
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05768464. Inclusion in this directory is not an endorsement.